Roche respects and proactively supports Human Rights.
“Protect, Respect and Remedy” are the three pillars of Harvard Professor John Ruggie’s framework which was approved by the UN Human Rights Council and adopted in the UN Guiding Principles on Business and Human Rights (UNGPs) in 2011.
Roche fully supports and implements the UNGPs, and is equally committed to supporting the following:
The UN Sustainable Development Goals (SDGs)
The 10 UN Global Compact Principles
The Universal Declaration of Human Rights
The International Labour Organization (ILO) Declaration on Fundamental Principles and Rights at Work
This commitment is embodied in our
To fulfill its corporate social responsibility, Roche is committed to delivering continuous improvement and maintaining best practice at a policy and process level, as well as in its management approaches.
Roche fosters human rights globally, both in our own operations and across our value chain. We are evolving our holistic approach in the value chain towards a proactive approach in improving human rights by committing to doing no harm and making an impactful positive contribution to society.
By applying the principle of ‘knowing and showing’, Roche is committed to avoiding adverse impacts on Human Rights by focusing on the perspective of the rights holder.
We have a risk management approach designed to systematically identify, assess, mitigate and adequately manage the risk of human rights violations, including the assessment of whether there are reasonable grounds to suspect child labour. The Group human rights risk assessment covers our own operations and third-party operations. Its purpose is to identify and assess the potential negative human rights impacts of our activities and business relationships with a focus on own operations and the upstream supply chain.
Continuous cycle
Identify and evaluate the relevant business relationships across our value chain
Gain a comprehensive understanding of the human rights risks that may arise throughout our core value chain
Identify areas for potential improvement
Gather relevant data by:
Reviewing human rights standards
Examining Roche’s own policies and practices
Evaluating corporate performance
Conducting internal interviews
Engaging with rights holders
Identify human rights risks Roche may potentially cause or contribute to through its own activities or which are directly linked to its operations, products or services by its business relationships
Assess, consolidate and prioritise impact-based risks
Define risk mitigation strategies/plans
Monitor risk mitigation strategies/plans
Collect feedback from both internal and external affected stakeholders (leverage materiality assessment process when possible)
Establish form and frequency of communication accessible to all intended audiences
Educate internal and external stakeholders
The following focus areas based on impact were identified in our own operations:
We embed Human Rights in our existing operations and daily business by multiple means:
Within and beyond our industry.
Within Roche and while doing business with our suppliers.
General awareness about Human Rights principles is provided Roche-wide as part of a global mandatory eLearning. The completion rate in 2024 was 99.06%. Additional awareness initiatives are provided at the local, regional and global levels.
Including Human Rights aspects in due diligence activities associated with suppliers and business partners.
Having solid agreements in place with our suppliers and business partners
Together with our peers we foster the protection of Human Rights through our work with organizations such as the Pharmaceutical Supply Chain Initiative (
Via multiple internal and external channels.
All Roche departments and functions contribute to respecting and protecting Human Rights. For example, every site has a Human Resource contact supporting compliance with related principles such as discrimination and harassment, as outlined in the
Roche holds its suppliers to high performance expectations concerning human rights that are aligned with our own values and principles. These are detailed in the Roche Supplier Code of Conduct that is referenced in every Roche contract. In order to enhance transparency within our sphere of influence, we also expect suppliers and business partners to actively assess and manage Human Rights risks in their own business partners.
Our human rights commitment for business partners is based on the Pharmaceutical Supply Chain Initiative (PSCI) Principles, which we are committed to. The Principles are referenced in all Roche contracts and embedded in the provisions of the Roche Supplier Code of Conduct, which all our suppliers commit to.
We conduct risk-based due diligence on potential and existing suppliers and business partners. Human Rights aspects are an integral part of the due diligence undertaken at the Group and Affiliate level, this includes by way of example:
1.
The
2. IT Tools
IT Tools support a consistent end-to-end process which allows for recurring and systematic due diligence activities and risk assessments.
3. Robust third party risk management
As part of Group human rights risk assessment the following focus areas based on impact were identified in our supply chain.
* Pharmaceutical Supply Chain Initiative (PSCI:go.roche.com/pscinitiative)
Roche has a formal process and methodology for assessing our suppliers to identify those at higher risk for Human Rights violations due to:
Being associated with an industry that is likely to employ vulnerable populations
Being located in a region at higher risk for Human Rights violations, per respected Human Rights indices
Being associated with government, media or internal reports of alleged behavior or operations that indicate real or potential noncompliance with the Roche Supplier Code of Conduct
Roche selects its counterparties for acquisitions and divestments carefully from a general compliance and reputational perspective which includes but is not limited to Human Rights. Roche applies industry standard due diligence questionnaires to address health, safety & environment and employment related questions among a wide array of further matters which may relate to Human Rights. Depending on the counterparties, further risk based due diligence actions may be undertaken to ensure that issues such as human right violations, are detected and addressed.
Inputs to our automated human rights risk assessment methodology that allows for traceability in the supply chain include an external perspective with risk assessment depending on four main externally available and recognised indexes: KidsRights Index, Global Slavery Index, OECD Index and Global Rights Index, using the following data:
Nature of product or service procurement category code identifying the supplier’s exact industry and the nature of its product or service – to assess associated human rights risk. We are looking for activities typically associated with vulnerable populations such as children, underage workers, migrants, local underprivileged communities and people with low levels of education.
Exact location of the business partner’s operations to assess if that area or region is associated with higher levels of human rights violations (i.e. limited regulation or enforcement).
History or new information on potential risk data input on external reports or concerns raised about a particular business partner, region or industry
Business partners identified as being at higher risk for human rights violations are included in a list of business partner auditable entities. These are scheduled for PSCI-based audits as part of our SSAV programme.
Roche selects its counterparties for acquisitions and divestments carefully from a general compliance and reputational perspective which includes but is not limited to Human Rights. Roche applies industry standard due diligence questionnaires to address health, safety & environment and employment related questions among a wide array of further matters which may relate to Human Rights. Depending on the counterparties, further risk based due diligence actions may be undertaken to ensure that issues such as human right violations, are detected and addressed.
4. Grievance mechanism
Employees as well as business partners are encouraged to speak up in good faith if they believe that a human rights violation has occurred. This also covers any reasonable concerns about the existence of a potential or actual adverse impact related to child labour.
The
All allegations are taken seriously and are objectively investigated. If the allegation is substantiated, we take appropriate remedial measures.
In 2024, 20 substantiated incidents related to human rights violations triggered terminations of contracts. All the incidents were related to discrimination and harassment, 18 involving Roche employees and 2 a contractor.None of the incidents involved a business partner.
In addition, we assess supplier compliance with our Human Rights standards through our Supplier Sustainability Assurance Visit (SSAV) audit program. In 2024:
We conducted 118 sustainability audits (SSAVs) at supplier sites (41 in EMEA, 62 in APAC, 6 in North America and 9 in LATAM).
We had 284 Human Rights related observations for issues such as excessive overtime and incorrect overtime compensation (16%), improper maintenance of HR and payroll documentation (12%), delayed, improper payment and calculation of wages (8%).
Each of the suppliers were findings were identified, was required to establish and make progress on a formal corrective action plan.
Each of the 69 suppliers were required to establish and make progress on a formal corrective action plan.
Logistics and transportation
Supply chain materials
Facilities and utilities
Workforce, training and employee services
Diagnostic instruments and software
Laboratory supplies
Engineering
Research and development
Supply chain services
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.